VIVUS stock traded down $0.12 during midday trading on Monday, reaching $4.10. 3,023 shares of the company traded hands, compared to its average volume of 50,809. The firm has a market capitalization of $45.60 million, a price-to-earnings ratio of -1.18 and a beta of 1.78. The business has a 50 day moving average of $4.01 and a two-hundred day moving average of $3.73. VIVUS has a 12 month low of $2.15 and a 12 month high of $5.78.
VIVUS (NASDAQ:VVUS) last issued its quarterly earnings data on Tuesday, August 6th. The biopharmaceutical company reported ($0.56) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($1.00) by $0.44. The company had revenue of $18.39 million for the quarter, compared to the consensus estimate of $16.88 million. Sell-side analysts forecast that VIVUS will post -2.44 earnings per share for the current fiscal year.
VIVUS, Inc operates as a specialty pharmaceutical company primarily in the United States and the European Union. The company offers Qsymia for the treatment of obesity as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body-mass index of 30 or greater (obese patients) or 27 or greater (overweight patients) in the presence of at least one weight-related comorbidity, such as hypertension, type 2 diabetes mellitus, or high cholesterol.
Recommended Story: Investing in Growth Stocks
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for VIVUS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VIVUS and related companies with MarketBeat.com's FREE daily email newsletter.